Frederick L. Locke, MD

Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.

Frederick Locke, MD, addresses the ongoing unmet needs for patients with mantle cell lymphoma such as the role of novel agents in the upfront setting.

Frederick Locke, MD, considers whether CAR T will gain a more significant role in mantle cell lymphoma and if it will move to the frontline setting.

Frederick Locke, MD, explains when to choose CAR T over BTK inhibitors, patient factors to consider for CAR T cell therapy, and when BTK inhibitors are best utilized.

Frederick Locke, MD, discusses the role of CAR T in patients with mantle cell lymphoma, the impact it has on autologous transplant, and when transplant is recommended.

Frederick Locke, MD, discusses the ZUMA-2 trial, including the study design, results, and practical implications for CAR T in patients with mantle cell lymphoma.

Frederick Locke, MD, reviews the treatment options historically available to patients with mantle cell lymphoma who had disease recurrence after high-dose therapy and transplant.

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.

Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.